Principal Investigator
Jay Spiegel
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20230616
Clinical Trial Summary
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Myeloma
Contact Information
Phone Number
305-243-2647